Sygnature Discovery
Edit

Sygnature Discovery

https://www.sygnaturediscovery.com/
Last activity: 18.04.2023
Active
Categories: AppBioTechBusinessClinicDevelopmentDrugMedtechProviderResearchService
Sygnature Discovery - enabling success in drug discovery

Sygnature Discovery (www.sygnaturediscovery.com ) is a leading independent provider of integrated drug discovery resource and expertise. Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).

We add considerable value to our clients'​ research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes. Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins). We can also provide pre-clinical experimental services support through our sister company RenaSci.

Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships. We have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.

In summary, Sygnature Discovery offers:

• Target validation
• Hit identification
• Hit-to-lead
• Lead optimisation
• Integrated drug discovery programmes
• Medicinal chemistry
• In vitro biology (including biophysics and live cell imaging)
• Computational chemistry
• DMPK
• Protein crystallography
Followers
1.76K
Followers
10.23K
Website visits
49.2K /mo.
Mentions
7
Location: United Kingdom, England, Nottingham
Employees: 201-500
Founded date: 2004

Investors 1

DateNameWebsite
-BioCitybiocity.co...

Mentions in press and media 7

DateTitleDescription
18.04.2023Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, ...
18.03.2022Sygnature Discovery Limited R & D status and future prospects of small molecule drugsSygnature Discovery Limited R & D status and future prospects of small molecule drugs High film permeability, attractiveness of new compounds similar to natural products …………………………………………………………………………………………… 20 Research system that leads ...
09.02.2021Sygnature wins Bionow Company of the YearSygnature Discovery, a leading provider of outsourced drug discovery services, has been named Company of the Year at the Bionow Annual Awards 2020. The goal of these awards is to highlight the outstanding success and achievements of those w...
11.09.2020GSK and J&J alum Vi­jay Red­dy to take con­trol of R&D at Tmu­ni­ty; An­drew Hirsch ex­its Agios for CEO job at C4 Ther­a­peu­ticsVi­jay Red­dy → Vi­jay Red­dy was seek­ing a re­turn to the US when he left his role as CMO at Lon­don-based Au­to­lus this sum­mer. Philadel­phia is that land­ing spot, as the T cell im­munother­a­py play­er Tmu­ni­ty has put him in charge...
26.06.2020In­ovio adds two to the lead­er­ship team; Adri­an Woolf­son is out at Sang­amo→ En­trenched in a le­gal bat­tle with their man­u­fac­tur­er that’s ev­i­dent­ly block­ing them from mak­ing their Covid-19 vac­cine can­di­date, In­ovio is mak­ing some lead­er­ship changes. Gene Kim will be pres­i­dent of In­ovio Asia, w...
12.09.2019Bay­er trims 2 top ex­ecs, shrinks man­age­ment board; Spring­Works boosts size of IPO→ Af­ter wel­com­ing J&J deal­mak­er Mar­i­anne De Backer to their team as BD chief a lit­tle more than a week ago, Bay­er an­nounced that it will be re­duc­ing the size of the com­pa­ny’s board of man­age­ment. Hart­mut Klusik and Ke­m...
15.02.2019J&J R&D vet Pe­ter Tum­mi­no joins the Big Phar­ma ex­o­dus, leap­ing to Nim­bus as CSO; Ca­dent taps Jodie Mor­ri­son for CEO→ Af­ter spend­ing the last 16 years as a re­searcher in Big Phar­ma, Pe­ter Tum­mi­no is go­ing biotech. Pe­ter Tum­mi­no Nim­bus re­ports that Tum­mi­no is join­ing the com­pa­ny as its new CSO af­ter his last stint at J&J, where he w...

Reviews 0

Sign up to leave a review

Sign up Log In